Mpox in HIV Version 2.0
Research type
Research Study
Full title
Impact of Mpox on people living with HIV
IRAS ID
326811
Contact name
Chloe Orkin
Contact email
Sponsor organisation
Queen Mary University of London
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
An outbreak of human Monkeypox occurred in 2022 and approximately 40% of those affected were people living with HIV. The predominant control strategy used during this outbreak was use of the modified vaccinia virus Ankara (MVA), a smallpox vaccine, as smallpox and monkeypox are genetically and structurally very similar. The MVA vaccine was also used as a vector for a HIV vaccine in the RIVER study and administered to individuals enrolled in control arm of this study. Samples taken for this study present an unique opportunity to study the serological and immunological responses to Monkeypox in people living with HIV.
REC name
Yorkshire & The Humber - Sheffield Research Ethics Committee
REC reference
23/YH/0148
Date of REC Opinion
11 Jul 2023
REC opinion
Further Information Favourable Opinion